

Bill No. 4229-08

APPOINTMENT


Approving the appointment of Donald Burke, M.D. to serve as a member of the Allegheny County Board of Health for a term to expire on January 11, 2012.

In Council September 23, 2008.

Read and approved by Motion of Council.



Rich Fitzgerald
President of Council

Attest: 

John Mascio
Chief Clerk of Council



DAN ONORATO
COUNTY EXECUTIVE

COUNTY OF ALLEGHENY

OFFICE OF THE COUNTY EXECUTIVE

101 COURTHOUSE • 436 GRANT STREET
PITTSBURGH, PA 15219
PHONE (412) 350-6500 • FAX (412) 350-6512
WWW.ALLEGHENYCOUNTY.US

4229-08

ALLEGHENY COUNTY COUNCIL

August 14, 2008

'08 AUG 14 AM 11:33

Honorable President and Members
Allegheny County Council
119 Courthouse
Pittsburgh, PA 15219

Dear Council Members:

Please find the attached resume of Donald Burke, M. D., whom I am recommending for appointment to the Allegheny County Board of Health.

The powers and duties of the Health Board are set out in Section 12011 of Act 315, Local Health Administration Law, as amended. This Board shall exercise rule making power by formulation of rules for the prevention of disease, removal of conditions which constitute a menace to health and promote and preserve public health. I am recommending Dr. Burke to serve a 4 year term ending on January 11, 2012, replacing Ann Francis.

Dr. Burke is the Dean of the Graduate School of Public Health at the University of Pittsburgh. Additionally he holds the positions of Associate Vice Chancellor for Global Health, and Director of the Center for Vaccine Research at the University of Pittsburgh. He is also the Jonas Salk Chair in Global Health at UPMC.

I appreciate your consideration, and ask you to act on this appointment as quickly as possible. Dr. Burke will make himself available for review before the appropriate committee if members of Council wish to speak with him.

Sincerely,

Dan Onorato
Allegheny County Executive

Donald Scott Burke, M.D.
1 June 2008

University of Pittsburgh / University of Pittsburgh Medical Center

Dean, Graduate School of Public Health
Associate Vice Chancellor for Global Health
Director, Center for Vaccine Research
UPMC – Jonas Salk Chair in Global Health

130 DeSoto Street, Room A624
Pittsburgh, PA 15261
Telephone 412-624-3001
Fax 412-624-3309
Email donburke@pitt.edu



EDUCATION AND TRAINING

Bachelor of Arts Degree, Western Reserve University, Cleveland, Ohio, 1967 (chemistry major; honors in biology; magna cum laude; Phi Beta Kappa)

Doctorate in Medicine, Harvard Medical School, Boston, Massachusetts, 1971

Clinical Fellow in Medicine (Intern & Junior Resident Physician), Harvard University and the Boston City Hospital, Boston, Massachusetts, 1971-73

Clinical Fellow in Medicine (Senior Resident Physician), Harvard University and the Massachusetts General Hospital, Boston, Massachusetts, 1975-76

Research Fellow in Infectious Diseases, Walter Reed Army Medical Center, Washington, DC, 1976-78

PAST EXPERIENCE

2002-2006: Associate Department Chairman and Program Director, Disease Prevention and Control Program, Department of International Health, Johns Hopkins Bloomberg School of Public Health. Led 42 full time Disease Prevention and Control faculty. Elected by vote of the faculty in 2002, re-elected in 2005.

1997-2006 Professor of International Health and Professor of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and Professor of Medicine, Johns Hopkins School of Medicine, and Director, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health. Principal Investigator, Johns Hopkins Cameroon Program, 1998-2003; Principal Investigator, Johns Hopkins HIV Vaccine Trials Unit (National Institutes of Health / NIAID, 1999-2006); Co-Principal Investigator, Mid-Atlantic Regional Center of Excellence for Biodefense (National Institutes of Health / NIAID, 2003-2006); Principal Investigator, "MIDAS" Modeling of Infectious Disease Agents Study (National Institutes of Health / NIGMS, 2004-present).

1996-1997: Associate Director for Emerging Threats and Biotechnology, Walter Reed Army Institute of Research (WRAIR). Responsible for design and implementation of research

programs on infectious diseases of military importance and new technologies in biomedicine. Coordinated global research activities on surveillance, diagnosis, prevention, and treatment of emerging infectious diseases. Retired from the US Army Medical Corps in 1997 as a Colonel after 23 years of active duty service.

- 1990-1996: Director, US Military HIV/AIDS Research Program, a nation-wide Army, Navy, and Air Force cooperative effort aimed at controlling HIV/AIDS in military populations. Directly or indirectly supervised and coordinated activities of 50 doctoral level and 150 technical and administrative personnel. Served as Area Manager for HIV/AIDS Research, US Army Medical Research and Materiel Command, responsible for distribution and management of retrovirus research funds, which averaged \$30 million per year. Emphasis on basic and applied research on HIV/AIDS vaccines.
- 1988-1990: Director, Division of Retrovirology, WRAIR, Washington, DC. Founder and Director, US Military HIV/AIDS Laboratory Complex, Rockville, Maryland. Responsible for design and conduct of US Military HIV/AIDS medical research studies, and for the management and direction of a 28,000 sq ft. laboratory complex of co-located Government, Jackson Foundation, and contractor facilities. Continued responsibilities for ongoing military HIV screening and medical staging programs.
- 1984-1988: Chief, Department of Virus Diseases, WRAIR. Responsible for the intramural research program on virus diseases of military importance, especially HIV/AIDS, flaviviruses, and hepatitis viruses. Responsible for the design and conduct of US military HIV screening and medical staging programs.
- 1978-1984: Chief, Virology Department, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand. Responsible for the design and conduct of research on tropical viruses of military importance, especially dengue and Japanese encephalitis viruses. Emphasis on studies related to vaccine development and testing. Also served as Deputy Director, AFRIMS, 1983-84.
- 1976-1978: Clinical Desk Officer, Department of Virus Diseases, WRAIR. Responsible for diagnostic virology at Walter Reed Army Medical Center. Simultaneously fulfilled clinical responsibilities as an Infectious Disease Fellow.
- 1973-1975: Clinical Ward Officer and Chief, Medical Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland. Responsible for occupational health of research workers in the high containment laboratories at USAMRIID. Conducted studies on vaccines against infectious disease agents of military significance.

MEDICAL CERTIFICATION AND LICENSE

Certified, Diplomat in the Specialty of Internal Medicine, American Board of Internal Medicine, 1977

Certified, Diplomat in the Sub-Specialty of Infectious Diseases, American Board of Internal Medicine, 1978

Medical License # D16350, State of Maryland, through 30 September 2008, with identification as a Specialist in Internal Medicine and in Infectious Diseases

PROFESSIONAL ACTIVITIES

Academic and Medical Appointments / US Military

Walter Reed Army Medical Center, Washington, DC
Attending Physician, Infectious Diseases Service, 1985- 1990
Staff Physician, Department of Medicine, 1985-1997

U.S. Army Command and General Staff College, Fort Leavenworth, Kansas
Faculty, Pre-Command Course, 1990-1992

Uniformed Services University of the Health Sciences, Bethesda, Maryland
Adjunct Associate Professor, Department of Preventive Medicine/Biometrics, 1985-1992
Associate Professor, Department of Medicine, 1987-1992
Professor, Department of Medicine, 1992-1997

Society Membership and Leadership

Chairman, Pediatric Dengue Vaccine Initiative
Elected Fellow, American Association for the Advancement of Science
Elected Fellow, American Academy of Microbiology
President (1995-96), American Society of Tropical Medicine and Hygiene
Fellow, Royal Society of Tropical Medicine and Hygiene (U.K.)
Fellow, American College of Physicians
Fellow, Infectious Disease Society of America
Member, American Public Health Association
Member, Physicians for Human Rights
Member, American Society for Virology
Member, American Association for the History of Medicine
Member, International AIDS Society

Consultations, Panels, and Boards

World Health Organization/SE Asia Regional Office, Temporary Advisor, on Research in Viral Hemorrhagic Fevers, 1980; on Dengue Hemorrhagic Fever, 1983; on Viral Hepatitis, 1984

Steering Committee on Dengue Vaccines, World Health Organization, Member, 1985-1988

Americans for a Sound AIDS Policy (ASAP) Advisory Council, Member, 1987-1992

AIDS Vaccine Research and Development Subgroup, US Public Health Service, DoD representative, 1987-1992

HIV Early Care Advisory Group, American Medical Association, Member, 1989-1990.

Diagnostic and Therapeutic Technology Assessment Panel, American Medical Association, Member, 1989-1991

Roundtable for the Development of Drugs and Vaccines against AIDS, Institute of Medicine, Member, 1989-1994

International Forum on AIDS Research, Institute of Medicine, Member, 1990 - 1992

Steering Committee on AIDS/HIV Vaccine Development, World Health Organization, Member, 1991-1994

HIV/AIDS Working Group, Center for Strategic and International Studies, Member, 1992-1994

Mahidol University, Consultant, Post-graduate Training in Virology in Response to the HIV/AIDS Epidemic, Bangkok, Thailand, 1993

Civil-Military Alliance Against HIV/AIDS, Co-Founder, 1993

Working Group on HIV Vaccine Development and International Field Trials of the Federal Coordinating Committee on Science, Engineering and Technology Committee on Life Sciences and Health, Co-Chairman, 1992-1994

Pharmaceutical Organization, Royal Thai Government, Consultant, on Local Production of HIV Vaccines, 1994

AIDS Vaccine Trials Data and Safety Monitoring Board, Member, National Institutes of Health, 1988-1996

UNAIDS, Temporary Advisor on HIV Molecular Epidemiology, 1996 and 2000

Vice-President's Working Group on HIV Vaccines and Therapeutics, White House, Member, 1996

American Association of Blood Banks, Consultant, Think Tank on Emerging Viruses, 1996

Ministry of Agriculture, Government of New Zealand, Consultant, on Rabbit Hemorrhagic Disease Virus as a Bio-control Agent, 1997

National Institutes of Health Study Section on Tropical Medicine and Parasitology, Member, 1997-2000

Food and Drug Administration, Transmissible Spongiform Encephalopathies Advisory Committee, Member, 1998-2002

National Research Council, Panel on Climate, Ecology, Infectious Diseases, and Health, Chairman, 1999-2001

Institute of Medicine, Department of Defense Global Emerging Infectious Surveillance Committee, Member, 2000-2001

International Research Institute for Climate Prediction of Columbia University, Scientific Advisory Committee, Member, 2000-2003

Institute of Medicine, Committee on Emerging Microbial Threats to Health in the 21st Century, Member, 2001-2003

Smallpox Computational Modeling Working Group, Office of Public Health Emergency Preparedness, US Department of Health and Human Services, Member, 2002-2004.

SARS Task Force, Defense Science Board, Department of Defense, Member, 2003-2004.

National Biodefense Analysis and Countermeasure Center, Department of Homeland Security, Working Group on Threat Prioritization, Chair, Virology Group, 2003-2004.

Federation of American Scientists, Biosecurity Education for Biology Graduate Students Project, Temporary Advisor, 2004.

International AIDS Vaccine Initiative, Co-founder, 1994-96; Senior Scientific Advisor, 1997-2002; Policy Advisory Board Member, 2003 – present

Institute of Medicine, Department of Defense / Veterans Affairs Medical Follow-up Agency, Member of the Board, 2002-2006

Physicians for Human Rights / Health Action AIDS, Executive Committee, 2003-present.

Data Safety and Monitoring Board, HIV Phase III Clinical Trial (Rayong Thailand), Member, 2004-present

Consortium for Conservation Medicine, Executive Committee, 2004-present

Bill & Melinda Gates Foundation, Technical Review Panel, HIV/AIDS Vaccines, Member, 2005

Special Review Panel of the Joint National Institutes of Health / National Science Foundation Ecology of Infectious Disease Program, Panel Chairman, 2005

Jewish Healthcare Foundation, Board Member, 2006-present

Community Health Committee of the UPMC Board of Directors, 2006-present

National Biodefense Analysis & Countermeasures Center, Science & Technology Advisory Committee, 2006-present

NSF IGERT Sociotechnical Systems Advisory Board, 2006

Welcome Trust / Bill & Melinda Gates Foundation Ad Hoc Advisory Meeting on Innovation in Research, Delegate, London, 2007.
Pediatric Dengue Vaccine Initiative, Board of Counselors, 2007-present
UPMC Community Health Committee Board of Directors, 2007 - present
UPMC International Medical and Scientific Advisory Board 2007 – present
Pittsburgh Regional Health Initiatives Board of Directors, 2007 – present
Institute of Medicine, Health Sciences Policy Board Member, 2008 – present
Scientific Advisory Board of the MRC Centre for Outbreak Analysis and Modeling, 2008 – present
NIH Blue Ribbon Panel, 2008 – present

Public Testimonies

“Quality Control of HIV Screening,” Subcommittee on Regulation and Business Opportunities, House Small Business Committee, US Congress, 19 October 1987
“Obstacles to Routine Early Diagnosis of HIV,” Subcommittee on Health and the Environment, House Energy and Commerce Committee, US Congress, 4 April 1989
“Progress on the Army’s HIV Research Program,” Subcommittee on Health and the Environment, House Energy and Commerce Committee, US Congress, 16 April 1991
“Opportunities in AIDS Research,” Subcommittee on Health and the Environment, House Energy and Commerce Committee, US Congress, 24 April 1992
“HIV Research in the US Military,” Subcommittee on Defense Technology, Acquisition, and Industrial Base, Senate Armed Services Committee, US Congress, 24 June 1993
“Tropical Infectious Disease Research Funding,” Subcommittee on Foreign Operations, Export Financing, and Related Programs, House Committee on Appropriations, US Congress, 31 March 1998
“Tropical Infectious Disease Research Funding,” Subcommittee on Defense, Senate Committee on Appropriations, US Congress, 11 May 1998
“Infectious Disease Research,” Subcommittee on Defense, Senate Committee on Appropriations, US Congress, 29 March 2000
“Baltimore City HIV/AIDS Prevention- A Public Health State of Emergency,” Baltimore City Council, 9 October 2002
“Tropical Infectious Diseases” Subcommittee on Foreign Operations, Export Financing, and Related Programs, House Committee on Appropriations, US Congress, 2 April 2003

Medical Journals

Editorial Board Member

AIDS Research and Human Retroviruses, 1987-1989
Journal of Acquired Immune Deficiency Syndromes, 1988-1998
American Journal of Tropical Medicine and Hygiene, 1988-1997
Biosecurity and Bioterrorism, 2002-present
Epidemics, 2008-present

Editorial Advisory Board Member

Current Opinions in Infectious Diseases, Section Editor on HIV and AIDS, 1993.
Global Change and Human Health, 2000-2002
Emerging Infectious Diseases, 1997-present
Journal of Infectious Diseases, 2008 - present

Columnist

AIDS and Society: International Research and Policy Bulletin, “Vaccine Watch” quarterly column, 1992-1994

Editorial Committee

Epidemiological Reviews, Vaccines and Public Health, 2005-2006

National Academies Reports

National Research Council, Board on Atmospheric Sciences and Climate.

Chairman, Committee on Climate, Ecosystems, Infectious Diseases, and Human Health, 1999-2001. Issued report entitled “Under the Weather: Climate, Ecosystems, and Infectious Disease,” 2001.

National Research Council, Policy and Global Affairs Committee.

Reviewer, Report on “Future Contributions of the Biosciences to Public Health, Agriculture, Basic Research, Counter-terrorism, and Non-Proliferation Activities in Russia,” 2004

National Research Council, Board on Life Sciences.

Review Coordinator, report on “Exploring the role of antiviral drugs in the eradication of polio,” 2006

Institute of Medicine, Medical Follow-up Agency.

Member, Committee to Review the Department of Defense Global Emerging Infections Surveillance and Response System, 2000-2001. Issued report entitled “Perspectives on the Department of Defense Global Emerging Infections Surveillance and Response System: A Program Review,” 2001

Reviewer, Report on “Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military,” 2002

Medical Follow-up Agency Board Member, 2002-2006

Member, Committee on Long-term Health Effects of Participation in Project SHAD, 2003-2006. Report in preparation.

Institute of Medicine, Board on Global Health.

Member, Committee on Emerging Microbial Threats to Health in the 21st Century, 2001-2003. Issued report entitled “Microbial Threats to Health: Emergence, Detection, and Response,” 2003

Reviewer, Report on “Human Resources at U.S. Ports of Entry to Protect the Public’s Health” (Interim Letter Report), 2004

Member, Committee on Assessment of Future Scientific Needs for Live Variola Virus, 2008-present

Institute of Medicine, Board on Health Promotion and Disease Prevention.

Reviewer, Report on "Gulf War and Health: Updated Literature Review of Sarin," 2004

Co-Chairman, Committee on Development of Reusable Facemasks for Use during an Influenza Pandemic. Issued report entitled "Facing the Flu: Reusability of Facemasks during an influenza pandemic," 2006

HONORS AND AWARDS

Military

National Defense Service Medal, 1973
Army Service Ribbon, 1973
Army Commendation Medal, 1975
Meritorious Service Medal, 1978
Humanitarian Service Medal, 1981
Armed Forces Reserve Medal, 1984
Overseas Ribbon, 1984
Meritorious Service Medal, First Oak Leaf Cluster, 1985
Meritorious Service Medal, Second Oak Leaf Cluster, 1986
Order of Military Medical Merit, 1989
Department of the Army "A" Proficiency Designator, Infectious Diseases, 1990
National Defense Service Medal, First Oak Leaf Cluster, 1991
Meritorious Service Medal, Third Oak Leaf Cluster, 1991
Legion of Merit, 1997

Medical and Public Health

Nathaniel A. Young Memorial Award of the American Committee on Arthropod-borne Viruses, American Society of Tropical Medicine and Hygiene, for outstanding contributions to arbovirology by a scientist under the age of 45 years, 1989
Kimble Methodology Award of the Conference of Public Health Laboratorians, for outstanding contributions to Public Health by development and implementation of HIV diagnostics, 1989
Bailey K. Ashford Medal of the American Society of Tropical Medicine and Hygiene, for outstanding achievements in tropical medicine by a society member under the age of 45 years, 1990
Sustaining Membership Award, Association of Military Surgeons of the US, for outstanding contributions to medical research, 1992
Elected President, American Society of Tropical Medicine & Hygiene, 1995-1996
Golden Apple Award (best teacher), Johns Hopkins School of Hygiene and Public Health, 1998-1999
Elected Fellow, American Academy of Microbiology, 2000
Elected Member, Delta Omega Public Health Honorary Society, 2000

Elected Fellow, American Association for the Advancement of Science (Medical Science),
2003
Elected Fellow, American Epidemiological Society, 2006
UPMC-Jonas Salk Chair in Global Health, University of Pittsburgh, 2006-present
Ambassador, Paul G. Rogers Society for Global Health Research, 2007

Visiting Professorships and Honorary Lectures

Dartmouth Medical School and Dartmouth College, Visiting Professor, 15-16 April 1993
Tulane University School of Public Health and Tropical Medicine, Visiting Professor, 1-3
March 1994
Harvard Medical School, Department of Microbiology and Molecular Genetics, Visiting
Lecturer, 28 February 1995
University of Pittsburgh School of Medicine, Department of Molecular Genetics and
Biochemistry, Visiting Professor, 1-2 May 1995
Presidential Address, American Society of Tropical Medicine and Hygiene, Baltimore,
Maryland, 3 December 1996
Chapman Binford Memorial Lecturer, American Society of Microbiology, Atlanta, Georgia, 9
November 1997
Invited Lecturer, 50th Anniversary Celebration of the University of Pittsburgh Graduate School
of Public Health, Pittsburgh, Pennsylvania, 19 February 1999
Thomas Francis, Jr. Annual Memorial Lecturer, University of Michigan School of Public
Health, Ann Arbor, Michigan, 28 March 2001
Distinguished Scientist Seminar, Marine Biological Laboratory, Woods Hole, Massachusetts, 8
November 2002
Centennial Anniversary Lecturer, American Society of Tropical Medicine and Hygiene,
Philadelphia, Pennsylvania, 3 December 2003.
Invited Lecturer, Annual Meeting of the National Academy of Sciences, Washington DC, 20
April 2004
Keynote Address, Annual Symposium, New York Academy of Medicine and the Royal Society
of Medicine, New York, New York, 13 June 2005
John C. Cutler Memorial Lecturer, University of Pittsburgh Graduate School of Public Health,
26 September 2006
Keynote Address, Annual Meeting of the US Department of Defense Global Emerging Infection
Surveillance and Response System, Louisville, Kentucky, 6 August 2007.
Keynote Address, Institute of Medicine Forum on Microbial Threats, Washington, DC, 4
December 2007.

UNIVERSITY ACTIVITIES / JOHNS HOPKINS

Bloomberg School of Public Health

Committee on Human Research (Institutional Review Board), Co-Chairman, 1998-2001
Committee on Appointments and Promotions, member, 2002 – 2006
Biodefense Leadership Group, member, 2001 - 2003
Department of International Health
Appointments and Promotions Committee, member, 1997-2006
Executive Committee, member 1997-2006

Curriculum Committee, member, 1997-2006
Admissions Committee, member, 1997-2003.
Director, Graduate Degree Program in Vaccine Science and Policy, 1997-2002
Director, Certificate Program in Vaccine Science and Policy, 1998-2006
Director, Graduate Degree Program in Disease Prevention and Control, 2002-2006
Associate Department Chairman for Disease Prevention and Control, 2002-2006

Johns Hopkins Medicine

Medical Archives Advisory Committee, member, 1998-2006

OTHER PROFESSIONAL INTERESTS

History of Medicine

Invited lectures on the history of microbiology and vaccines. Some examples:

- *Jesse Lazear of Hopkins: The First Fallen Yellow Fever Hero*. Tropical Medicine Dinner Club of Baltimore, Baltimore, Maryland, 8 November 2000
- *Malaria Research at Johns Hopkins, 1884 – 1897*. Banquet Speaker, Inaugural Meeting of the Johns Hopkins Malaria Institute, Baltimore, Maryland, 27 January 2002
- *History of the American Society of Tropical Medicine and Hygiene, 1903-2003*. Centennial Celebration Plenary Address, ASTMH, Philadelphia, Pennsylvania, 3 December, 2003
- *Why Was West Nile Virus Originally Isolated? Events leading to the virus isolation in Uganda in 1937*. Invited Lecture, International Congress of Tropical Medicine and Malaria, Marseille, France, 14 September 2005
- *Historical Perspective of Chikungunya Virus Epidemiology and Outbreaks*. Invited Lecture, American Society of Tropical Medicine and Hygiene, Washington DC, 15 December 2005

Serve as Archivist for the American Society of Tropical Medicine and Hygiene and the American Committee on Arthropod-borne Viruses, (1998 – present).

Languages

Thai: Certificate of Literacy (reading and writing), Royal Thai Government, 1983
French: Fair reading, writing, and speaking abilities

PUBLICATIONS

Peer Reviewed Journal Articles

1. Rushforth NB, **Burke DS**. Behavioral and electrophysiological studies of hydra, II. Pacemaker activity of isolated tentacles. *Biol Bull* 140:502-519 (1971).
2. **Burke DS**. Cardiac monitor malfunction simulating bizarre rhythm. *Postgrad Med* 60:265-66 (1976).
3. **Burke DS**. Immunization against tularemia: Analysis of the effectiveness of live *Francisella tularensis* vaccine in prevention of laboratory-acquired tularemia. *J Infect Dis* 135:55-60 (1976)

4. Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, **Burke DS**, O'Malley TA, Goroll AH, Caplan CH, Nolan J, Carabello B, Slater EE. Multifactorial index of cardiac risk in noncardiac surgical procedures. *New Engl J Med* 297:845-850 (1977).
5. Oster CN, **Burke DS**, Kenyon RH, Ascher MS, Harber P, Pedersen CE. Laboratory-acquired Rocky Mountain Spotted Fever: The hazard of aerosol transmission. *New Engl J Med* 297:859-863 (1977).
6. **Burke DS**, Ramsburg HH, Edelman R. Persistence in humans of antibody to subtypes of Venezuelan Equine Encephalitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. *J Infect Dis* 136:354-359 (1977).
7. **Burke DS**, Ullian RB. Megaesophagus and pneumonia associated with *Mycobacterium chelonae*: A case report and a literature review. *Am Rev Resp Dis* 116:1110-1107 (1977).
8. Goldman L, Caldera DL, Southwick FS, Nussbaum SR, Murray B, O'Malley TA, Goroll AH, Caplan CH, Nolan J, **Burke DS**, Krogstad D, Carabello B, Slater EE. Cardiac risk factors and complications in non-cardiac surgery. *Medicine* 57:357-370 (1978).
9. Fine D, Mosher D, Yamada T, **Burke DS**, Kenyon R. Coagulation and complement studies in Rocky Mountain Spotted Fever. *Arch Intern Med* 138:735-738 (1978).
10. **Burke DS**, Madoff S. Infection of a traumatic pelvic hematoma with *Mycoplasma hominis*. *Sex Transm Dis* 5:65-67 (1978).
11. Light JA, **Burke DS**. Association of cytomegalovirus (CMV) infections with increased recipient mortality following transplantation. *Transplant Proc* 11:79-82 (1979).
12. **Burke DS**, Gaydos JC, Hodder RA, Bancroft WH. Seroimmunity to polioviruses in U.S. Army recruits. *J Infect Dis* 139:225-227 (1979).
13. **Burke DS**, Brown SL. Lack of diagnostic utility of febrile agglutinin screens. *Military Med* 145:624-627 (1980).
14. **Burke DS**, Nimmannitya S. Passively acquired antibody to hepatitis A virus in Thai infants. *Southeast Asian J Trop Med Pub Health* 11:415 (1980).
15. **Burke DS**, Snitbhan R, Johnson DE, Scott RM. Age specific prevalence of hepatitis A virus antibody in Thailand. *Am J Epidemiol* 113:245-249 (1980).
16. Johnson DE, **Burke DS**, Williams RG, Murray BE. Observations on medical care in a refugee camp in Thailand. *Military Med* 146:842-845 (1981).
17. Nimmannitya S, Nisalak A, **Burke DS**. Passively acquired antibody to flaviviruses in Thai infants. *SEAsian J Trop Med Pub Health* 12:344-345 (1981).
18. **Burke DS**, Churchill FE Jr, Gaydos JC, Kaufman L. Epidemic histoplasmosis in patients with undifferentiated fever. *Military Med* 147:466-467 (1982).
19. Tingpalapong M, Whitmire RE, Watts DM, **Burke DS**, Binn LN, Tesapruteep T, Laungtongkum S, MarchwickRH. Epizootic of viral enteritis in dogs in Thailand. *Am J Vet Res* 43:1687-1690 (1982).
20. Watts DM, Harrison BA, Nisalak A, Scott RM, **Burke DS**. Evaluation of *Toxorhynchites splendens* (Diptera: Culicidae) as a bioassay host for dengue viruses. *J Med Entomol* 19:54-59 (1982).
21. **Burke DS**, Nisalak A. Detection of Japanese encephalitis virus Immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. *J Clin Micro* 15:353-361 (1982).
22. **Burke DS**, Nisalak A, Ussery MA. Antibody capture immunoassay detection of Japanese encephalitis virus immunoglobulin M and G antibodies in cerebrospinal fluid. *J Clin Microbiol* 16:1034-1042 (1982).
23. Lam K-W, **Burke DS**, Siemens M, Cipperly V, Li C-Y, Yam LT. Characterization of serum acid phosphatase associated with dengue hemorrhagic fever. *Clin Chem* 28:2296-2299 (1982).
24. Gilbreath MJ, Pavanand K, MacDermott RP, Ussery M, **Burke DS**, Nimmannitya S, Tulyayon S. Cold-reactive immunoglobulin M antilymphocyte antibodies directed against B cells in Thai children with dengue hemorrhagic fever. *J Clin Microbiol* 17:672-676. (1983).

25. Echeverria P, **Burke DS**, Blacklow NR, Cukor G, Charoenkul C, Yanggratoke S. Age-specific prevalence of antibody to rotavirus, Escherichia coli, heat-labile enterotoxin, Norwalk virus, and hepatitis A virus in a rural community in Thailand. *J Clin Microbiol* 17:923-925 (1983).
26. Srivatanakul P, **Burke DS**, Thanasombutt S, and Tanngarmtron D. Serum markers of hepatitis A and B virus infection in Thai patients with primary hepatocellular carcinoma. *Thai Cancer J* 9:113-118 (1983).
27. **Burke DS**, Heisey GB. Wild Malaysian cynomolgus monkeys are exposed to hepatitis A virus. *Am J Trop Med Hyg* 33:940-944 (1984).
28. Brown GW, Shirai A, Jegathesan M, **Burke DS**, Twartz JC, Saunders P, and Huxsoll DL. Febrile illness in Malaysia - An analysis of 1,629 hospitalized patients. *Am J Trop Med Hyg* 33:311-315 (1984).
29. Henchal EA, McCown JM, **Burke DS**, Seguin MC, Brandt WE. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. *Am J Trop Med Hyg* 34:162-169 (1985).
30. **Burke DS**, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S. Kinetics of IgM and IgG Responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. *J Infect Dis* 151:1093-1099 (1985).
31. **Burke DS**, Tingpalapong M, Ward GS, Andre R, Leake CJ. Intense transmission of Japanese encephalitis virus to pigs in a region free of epidemic encephalitis. *Southeast Asian J Trop Med Pub Health* 16:199-206 (1985).
32. **Burke DS**, Tingpalapong M, Elwell MR, Paul PS, VanDeusen RA. Japanese encephalitis virus immunoglobulin M antibodies in porcine sera. *Am J Vet Res* 46:2054-2057 (1985).
33. **Burke DS**, Chatiyononda K, Anandrik S, Nakornsri S, Nisalak A, Hoke CH. Improved surveillance of Japanese encephalitis by detection of virus-specific IgM in desiccated blood samples. *Bull Wld Health Org* 63:1037-1042 (1985).
34. **Burke DS**, Lorsomrudee W, Leake CJ, Hoke CH, Nisalak A, Chongswasdi V, Laorkapongse T. Fatal outcome in Japanese encephalitis. *Am J Trop Med Hyg* 34:1203-1210 (1985).
35. **Burke DS**, Nisalak A, Lorsomrudee W, Ussery MA, Laorpongse T. Virus-specific antibody-producing cells in blood and cerebrospinal fluid in acute Japanese encephalitis. *J Med Virol* 17:283-292 (1985).
36. Watts DM, Harrison BA, Pantuwatana S, Klein TA, **Burke DS**. Failure to detect natural transovarial transmission of dengue virus by *Aedes aegypti* and *Aedes albopictus* (Diptera: Culicidae). *J Med Entomol* 22:261-265 (1985).
37. Johnson RT, **Burke DS**, Elwell M, Leake CJ, Nisalak A, Hoke CH, Lorsomrudee W. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. *Ann Neurol* 18:567-573 (1985).
38. Tingpalapong M, Hoke CH, Ward GS, **Burke DS**, Elwell MR, Lohytyothin S, Saisombat S. Anti-rabies virus Ig in serum and cerebrospinal fluid from rabid dogs. *Southeast Asian J Trop Med Pub Hlth* 17:550-557 (1986).
39. **Burke DS**, Nisalak A, Hoke CH. Field trial of a Japanese encephalitis diagnostic kit. *J Med Virol* 18:41-49 (1986).
40. Leake CJ, **Burke DS**, Nisalak A, Hoke CH. Isolation of Japanese encephalitis virus from clinical specimens using a continuous mosquito cell line. *Am J Trop Med Hyg* 35:1045-1050 (1986).
41. Monath TP, Wands JR, Hill LJ, Brown NV, Marciniak RA, Wong MA, Gentry MK, **Burke DS**, Grant JA, Trent DW. Geographic classification of dengue-2 virus strains by antigen signature analysis. *Virology* 154:313-324 (1986).
42. Leake CJ, Ussery MA, Nisalak A, Hoke CH, Andre RG, **Burke DS**. Virus isolations from mosquitoes collected during the 1982 Japanese encephalitis epidemic in northern Thailand. *Trans Roy Soc Trop Med Hyg* 80:831-837 (1986).
43. Sjogren MH, Tanno H, Fay O, Sileoni S, Cohen BD, **Burke DS**, Feighny RJ. Hepatitis A virus in stool during clinical relapse. *Ann Int Med* 106:221-226 (1987).

44. **Burke DS**, Morrill JE. Levels of Interferon in the plasma and cerebrospinal fluid of patients with acute Japanese encephalitis. *J Infect Dis* 155:797-799 (1987).
45. Watts DM, **Burke DS**, Harrison BA, Whitmire RE, Nisalak A. Effect of temperature on the vector efficiency of *Aedes aegypti* for dengue-2 virus. *Am J Trop Med Hyg* 36:143-152 (1987).
46. **Burke DS**, Nisalak A, Gentry MK. Detection of flavivirus antibodies in human serum by epitope-blocking immunoassay. *J Med Virol* 23:165-173 (1987).
47. **Burke DS**, Redfield RR, Putman P, Alexander SS. Variations in Western blot banding patterns of Human T-Cell Lymphotropic Virus Type III/Lymphadenopathy-associated Virus. *J Clin Microbiol* 25:81-84 (1987).
48. Redfield RR, Wright DC, James WD, Jones TS, Brown C, **Burke DS**. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. *N Engl J Med* 316:673-676 (1987).
49. **Burke DS**, Brandt BL, Redfield RR, Lee T-H, Thorne RM, Beltz GA, Hung C-H. Diagnosis of Human Immunodeficiency Virus infection by immunoassay using a molecularly cloned and expressed virus envelope polypeptide. Comparison to Western blot on 2707 consecutive serum samples. *Ann Int Med* 106:671-676 (1987).
50. **Burke DS**, Brundage JF, Bernier W, Gardner LI, Redfield RR, Gunzenhauser J, Voskovitch J, Herbold JR. Demography of HIV infections among civilian applicants for military service in four counties in New York City. *NY State J Med* 87:262-264 (1987).
51. Redfield RR, **Burke DS**. Shadow on the Land: The Epidemiology of HIV infection. *Viral Immunol* 1:69-81 (1987).
52. Rhoads JL, Wright DC, Redfield RR, **Burke DS**. Chronic vaginal candidiasis in women with Human Immunodeficiency infection. *J Am Med Assoc* 257:3105-3107 (1987).
53. **Burke DS**, Brundage JF, Herbold JR, Berner W, Gardner LI, Gunzenhauser JD, Voskovitch J, Redfield RR. Human Immunodeficiency Virus infections among civilian applicants for United States military service, October 1985 to March 1986. *N Engl J Med* 317:132-136 (1987).
54. **Burke DS**, Nisalak A, Johnson DE, Scott RMcN. A prospective study of dengue infections in Bangkok. *Am J Trop Med Hyg* 38:172-180 (1988).
55. Kliks SC, Nimmanitya S, Nisalak A, **Burke DS**. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. *Am J Trop Med Hyg* 38:411-419 (1988).
56. Walker PJ, Henchal EA, Blok J, Repik PM, Henchal LS, **Burke DS**, Robbins SJ, Gorman BM. Variation in dengue type 2 viruses isolated in Bangkok during 1980. *J Gen Virol* 69:591-602 (1988).
57. Putnak JR, Charles PC, Padmanabhan R, Irie K, Hoke CH, **Burke DS**. Functional and antigenic domains of the dengue-2 virus nonstructural glycoprotein NS-1. *Virology* 163:93-103 (1988).
58. Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, **Burke DS**, Bancroft WH. Virulence of a live dengue virus vaccine candidate: A possible new marker of dengue virus attenuation. *J Infect Dis* 158:876-880 (1988).
59. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasene S-O, Gingrich JB, Latendresse J, Fukai K, **Burke DS**. Protection against Japanese encephalitis by inactivated vaccines. *N Engl J Med* 319:608-614 (1988).
60. Brundage JF, **Burke DS**, Gardner LI, Visintine R, Peterson M, Redfield RR. HIV infection among young adults in the New York area: Prevalence and incidence estimates based on antibody screening among civilian applicants for military service. *NY State J of Med* 88:232-235 (1988).
61. Warrell MJ, Looareesuwan S, Manatsathit S, White NJ, Phuapradit P, Vejajiva A, Hoke CH, **Burke DS**, Warrell DA. Rapid diagnosis of rabies and post-vaccinal encephalitides. *Clin Exp Immunol* 71:229-234 (1988).
62. **Burke DS**, Brundage JF, Redfield RR, Damato JJ, Schable CA, Putman P, Visintine R, Kim HI. Measurement of the false positive rate in a screening program for Human Immunodeficiency Virus infections. *N Engl J Med* 319:961-964 (1988).

63. Damato JJ, Fipps DR, Redfield RR, **Burke DS**. The Department of the Army quality assurance program for Human Immunodeficiency Virus antibody testing. *Lab Med* 19:577-580 (1988).
64. Damato JJ, Kim H, Fipps DR, Wylie N, **Burke DS**. High-resolution HIV Western blot methodology using Bio Rad Mini Protein II Test System. *Lab Med* 19:753-756 (1988).
65. Fipps DR, Damato JJ, Brandt B, **Burke DS**. Effects of multiple freeze thaws and various temperatures on the reactivity of Human Immunodeficiency Virus antibody using three detection assays. *J Virol Methods* 20:127-132 (1988).
66. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, **Burke DS**, Skillman D, Meltzer MS. Efficient isolation and propagation of Human Immunodeficiency Virus on recombinant colony-stimulating factor 1-treated monocytes. *J Exp Med* 167:1428-1441 (1988).
67. Looney DJ, Fisher AG, Putney SD, Rusche JR, Redfield RR, **Burke DS**, Gallo RC, Wong-Staal F. Type-restricted neutralization of molecular clones of Human Immunodeficiency Virus. *Science* 241:357-359 (1988).
68. Fipps DR, Damato JJ, **Burke DS**. Effects of heat inactivation on HIV antibody screening and confirmatory test systems. *Diag Micro Infect Dis* 10:103-107 (1988).
69. Redfield RR, **Burke DS**. HIV Infection: The Clinical Picture. *Scientific American* 256: 90-98 (1988).
70. Kliks SC, Nisalak A, Brandt WE, Wahl L, **Burke DS**. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. *Am J Trop Med Hyg* 40:444-451(1989).
71. Mason PW, Dalrymple JM, Gentry MK, McCown JM, Hoke CH, **Burke DS**, Fournier MJ, Mason TL. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. *J Gen Virol* 70:2037-2049 (1989).
72. Kaufman BM, Summers PL, DuBois DR, Cohen WH, Gentry MK, Timchak RL, **Burke DS**, Eckels KH. Monoclonal antibodies for dengue virus PRM glycoprotein protect mice against lethal dengue infection. *Amer J Trop Med Hyg* 41:576-580 (1989).
73. Shafferman A, Lennox J, Grosfeld H, Sadoff J, Redfield RR, **Burke DS**. Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection. *AIDS Res Hum Retro* 5:33-39 (1989).
74. Rickman WJ, Waxdal MJ, Monical C, Damato JD, **Burke DS**. Department of Army lymphocyte immunophenotyping quality assurance program. *Clin Immunol Immunopathol* 52:85-95 (1989).
75. Gardner LI, Jr, Brundage JF, **Burke DS**, McNeil JG, Visintine R, Miller RN. Spatial diffusion of the Human Immunodeficiency Virus infection epidemic in the United States, 1985-1987. *Ann Assoc Am Geograph* 79:25-43 (1989).
76. McNeil JG, Brundage JF, Wann ZF, **Burke DS**, Miller RN, and the Walter Reed Retrovirus Research Group. Direct measurement of Human Immunodeficiency Virus seroconversions in a serially tested population of young adults in the United States Army, October 1985 to October 1987. *N Engl J Med* 320:1581-1585 (1989).
77. Shafferman A, Layne A, Sadoff J, **Burke DS**, Morton WR, Benveniste RE. Antibody recognition of SIV envelope peptides in plasma from macaques experimentally infected with SIVmne. *AIDS Res Hum Retro* 5:327-336 (1989).
78. **Burke DS**. Laboratory diagnosis of Human Immunodeficiency Virus infection. *Clin Lab Med* 9:369-392 (1989).
79. Gardner LI, Brundage JF, **Burke DS**, McNeil JG, Visintine R, Miller RN. Evidence for spread of the Human Immunodeficiency Virus epidemic into low prevalence areas of the United States. *J AIDS* 2:521-532 (1989).
80. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, **Burke DS**. Sources of variability in repeated T-helper lymphocyte counts from Human Immunodeficiency virus Type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. *J AIDS* 3:144-151 (1990).

81. Brundage JF, McNeil JG, Miller RN, Gardner LI, Harrison SM, Hawkes C, Craig DB, Redfield RR, **Burke DS**. The current distribution of CD4+ T-lymphocyte counts among adults in the United States with Human Immunodeficiency Virus infections: Estimates based on the experience of the US Army. *J AIDS* 3:92-94 (1990).
82. Kelly PW, Miller RN, Pomerantz R, Wann F, Brundage JF, **Burke DS**. Human Immunodeficiency Virus seropositivity among members of the active duty U.S. Army, 1985-1989. *Am J Pub Hlth* 80:405-410 (1990).
83. Gomatos PJ, Stamatos NM, Gendelman HE, Fowler A, Hoover DL, Kalter DC, **Burke DS**, Tramont EC, Meltzer MS. Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells. *J Immunol* 144:4183-4188 (1990).
84. **Burke DS**, Brundage JF, Goldenbaum M, Gardner LI, Peterson M, Visintine R, Redfield RR. Human Immunodeficiency Virus infections in teenagers: Seroprevalence among applicants for US military service. *J Am Med Assoc* 263:2074-2077 (1990).
85. **Burke DS**, Fowler AK, Redfield RR, Dilworth S, Oster CN. Isolation of HIV-1 from the blood of seropositive adults: Patient stage of illness and sample inoculum size are major determinants of a positive culture. *J AIDS* 3:1159-1167 (1990).
86. Brundage JF, **Burke DS**, Gardner LI, McNeil JG, Goldenbaum M, Visintine R, Redfield RR, Peterson M, Miller RN. Tracking the spread of the HIV infection epidemic among young adults in the United States: results of the first four years of screening among civilian applicants for U.S. military service. *J AIDS* 3:1168-1180 (1990).
87. Cowan DN, Pomerantz RS, Wann ZF, Goldenbaum M, Brundage JF, Miller RN, **Burke DS**, Carroll CA, and the Walter Reed Retrovirus Research Group. Human Immunodeficiency Virus infection among members of the Reserve Components of the US Army: Prevalence, incidence, and demographic characteristics. *J Infect Dis* 162:827-836 (1990).
88. Birx D, Redfield RR, Tencer K, Fowler A, **Burke DS**, and Tosato G. Induction of interleukin-6 during Human Immunodeficiency Virus Infection. *Blood* 76:2303-2310 (1990).
89. Humphrey M, Mosca J, Baker JR Jr, Drabick JJ, Carr FE, **Burke DS**, Wartofsky L, Djuh Y-Y, and Burman KD. Absence of retroviral sequences in Graves disease. *Lancet* 337:17-18 (1991).
90. Birx DL, Rhoads JL, Wright JC, **Burke DS**, Redfield RR. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. *J AIDS* 4:188-196 (1991).
91. Wages JM Jr., Hamdallah M, Calabro MA, Fowler AK, Oster CN, Redfield RR, and **Burke DS**. Clinical Performance of a polymerase chain reaction testing algorithm for diagnosis of HIV-1 infection in peripheral blood mononuclear cells. *J Med Virol* 33:58-63 (1991).
92. Michael NL, Morrow P, Mosca J, Vahey M, **Burke DS**, and Redfield RR. Induction of Human Immunodeficiency Virus Type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. *J Virol* 65:1291-1303 (1991).
93. McNeil JG, Brundage JF, Gardner LI, Wann ZF, Razullo PO, Redfield RR, **Burke DS**, Miller RN. Trends of HIV seroconversion among young adults in the US Army, 1985 to 1989. *J Am Med Assoc* 265:1709-1714 (1991).
94. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzbica T, Shafferman A, Volvovitz F, Oster C, **Burke DS**, and the Military Medical Consortium for Applied Retroviral Research. A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early Human Immunodeficiency Virus infection. *N Engl J Med* 324:1677-1684 (1991).
95. Cowan DN, Brundage JF, Pomerantz RS, Miller RN, **Burke DS**. HIV infection among members of the US Army Reserve Components with medical and health occupations. *J Am Med Assoc* 265:2826-2830 (1991).
96. Drabick JJ, Horning VL, Lennox JL, Coyne PE, Oster CN, Knight RD, Dillard TA, Fuller SA, Damato JJ, **Burke DS**. A retrospective analysis of diseases associated with indeterminate HIV western blot patterns. *Military Med* 156:93-96 (1991).

97. Damato JJ, O'Bryen BN, Fuller SA, Roberts CR, Redfield RR, **Burke DS**. Resolution of indeterminate HIV-1 test data using the Department of Defense HIV-1 testing program. *Lab Medicine* 22:107-113 (1991).
98. Michael NL, **Burke DS**. Natural history of human immunodeficiency virus infection. *Dermatol Clin* 9:429-941 (1991).
99. Shafferman A, Jahrling PB, Benveniste RE, Lewis MG, Phipps TJ, Eden-McCutchan F, Sadoff J, Eddy GA, **Burke DS**. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. *Proc Natl Acad Sci* 88:7126-7130 (1991).
100. Rosenberg YJ, White BD, Papemaster SF, Zack P, Jarling PB, Eddy GA, **Burke DS**, Lewis MG. Variation in T-lymphocyte activation and susceptibility to SIVPBj-14-induced acute death in macaques. *J Med Primatol* 20:206-210 (1991).
101. McCutchan FE, Sanders-Buell E, Oster CW, Redfield RR, Hira SK, Perine PL, Ungar BLP, **Burke DS**. Genetic comparison of Human Immunodeficiency Virus (HIV-1) isolates by polymerase chain reaction. *J AIDS* 4:1241-1250 (1991).
102. Rhoads JL, Birx DL, Wright DC, Brundage JF, Brandt BL, Redfield RR, **Burke DS**. Safety and immunogenicity of multiple conventional immunizations administered during early HIV infection. *J AIDS* 4:724-731 (1991).
103. Michael NL, Vahey M, **Burke DS**, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. *J Virol* 66:310-316 (1992).
104. Roberts CR, Fipps DR, Brundage JF, Wright SE, Goldenbaum M, Alexander SS, **Burke DS**. Prevalence of human T-lymphotropic virus in civilian applicants for the United States Armed Forces. *Am J Pub Hlth* 82:70-73 (1992).
105. **Burke DS**. Human HIV Vaccine Trials: Does antibody-dependent enhancement pose a genuine risk? *Perspect Biol Med* 35:511-530 (1992).
106. Nkya WM, Warren RQ, Wolf H, Hendrix CW, Tesha J, Redfield RR, Melcher GP, **Burke DS**, Kanda P, Kennedy RC. Fine specificity of the humoral immune response to HIV-1 Gp160 in HIV-1 infected individuals from Tanzania. *J Med Virol* 37:61-66 (1992).
107. McCutchan FE, Ungar BLP, Hegerich P, Roberts CR, Fowler AK, Hira SK, Perine PL, **Burke DS**. Genetic analysis of HIV-1 isolates from Zambia and an expanded phylogenetic tree for HIV-1. *J AIDS* 5:441-449 (1992).
108. Shafferman A, Lewis MG, McCutchan FE, Benveniste RE, Jahrling PB, Hickman RL, Lai C-Y, **Burke DS**, Eddy GA. Vaccination of macaques with SIV conserved envelope peptides suppressed infection and prevented disease progression and transmission. *AIDS Res Hum Retroviruses* 8:1483-1487 (1992).
109. McCutchan FE, Hegerich PA, Brennan TP, Phanuphak P, Singharaj P, Jugsudee A, Berman PW, Gray AM, Fowler AK, **Burke DS**. Genetic variants of HIV-1 in Thailand. *AIDS Res Hum Retroviruses* 8: 1887-1895 (1992).
110. Tramont EC, **Burke DS**. AIDS/HIV in the US Military. *Vaccine* 11:529-533 (1993).
111. Roy MJ, Damato JJ, **Burke DS**. Absence of true seroreversion of HIV-1 antibody in seroreactive individuals. *J Am Med Assoc* 269:2876-2879 (1993).
112. Kim JH, Mosca JD, Vahey MT, McLinden RJ, **Burke DS**, Redfield RR. Consequences of Human Immunodeficiency Virus Type 1 superinfection of chronically infected cells. *AIDS Res Hum Retroviruses* 9:875-882 (1993).
113. Birx DL, Brundage J, Larson K, Engler R, Smith L, Squire E, Carpenter G, Sullivan M, Rhoads J, Oster C, James W, Lupton G, Wierzbza T, **Burke DS**, Redfield RR. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. *J AIDS* 6:1248-1257 (1993).
114. **Burke DS**. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. *Vaccine* 11:795-804 (1993).

115. Shafferman A, Lewis MG, McCutchan FE, Benveniste RE, Jahrling PB, **Burke DS**, Eddy GA. Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge. *Vaccine* 11:848-852 (1993).
116. **Burke DS**. Vaccine therapy for HIV: A historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. *Vaccine* 11:883-891(1993).
117. Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead SB, **Burke DS**. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. *AIDS Res Human Retrovirus* 9:1175-1184 (1993).
118. Mascola JR, **Burke DS**. Antigen detection in neutralization assays: High levels of interfering anti-p24 antibodies in some plasma. *AIDS Res Hum Retrovirus* 9:1173-1174 (1993).
119. Lewis MG, Elkins WR, McCutchan FE, Beneveniste RE, Lai CY, Montefiori DC, **Burke DS**, Eddy GA, Shafferman A. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. *Vaccine* 11:1347-1355 (1993).
120. Louwagie J, McCutchan FE, Peeters M, Brennan TP, Sanders-Buell E, Eddy GA, van der Groen G, Fransen K, Gershy-Damet GM, Deleys R, **Burke DS**. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. *AIDS* 7:769-780 (1993).
121. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, **Burke DS**. Two antigenically distinct subtypes of Human Immunodeficiency Virus Type 1: Viral genotype predicts neutralization serotype. *J Infect Dis* 169:48-54 (1994).
122. Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, Beckett LA, Roberts CR, Winslow D, **Burke DS**. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. *Antimicro Agents Chemother* 38:307-314 (1994).
123. Louwagie J, Delwart EL, Mullins JI, McCutchan FE, Eddy G, **Burke DS**. Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. *AIDS Res Human Retrovirus* 10:561-567 (1994).
124. Carroll R, Lin JT, Dacquel EJ, Mosca JD, **Burke DS**, St Louis DC. A Human Immunodeficiency Virus Type 1 (HIV-1) -based retroviral vector system utilizing stable HIV-1 packaging cell lines. *J Virol* 68:6047-6051 (1994).
125. Biselli R, Loomis LD, Del Bono V, **Burke DS**, Redfield RR, Birx DL. Immunization of HIV-infected patients with rgp160: Modulation of anti-rgp120 antibody spectrotpe. *J AIDS* 7:1016-1024 (1994).
126. Vahey M, Birx DL, Michael NL, **Burke DS**, Redfield RR. Assessment of gag DNA and genomic RNA in peripheral blood mononuclear cells in HIV-infected patients receiving intervention with a recombinant gp 160 subunit vaccine in a phase I study. *AIDS Res Human Retrovirus* 10:649-654 (1994).
127. VanCott TC, Bethke FR, Kalyanaraman V, **Burke DS**, Redfield RR, Birx DL. Preferential antibody recognition of structurally distinct HIV-1 gp120 molecules. *J AIDS* 7:1103-1115 (1994).
128. Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, Wolfe AD, Garcia GE, Doctor BP, **Burke DS**, Gordon RK, Lane JR, Chiang PK. Anti-Human Immunodeficiency Virus 1 (HIV-1) activities of 3-Deaza-adenosine Analogs: Increased potency against 3-azido-3-dexythyminidine-resistant HIV-1 strains. *Proc Natl Acad Sci USA* 92:215-219 (1995).
129. Louwagie J, Janssens W, Mascola J, Heyndrickx L, Hegerich P, van der Groen G, McCutchan FE, **Burke DS**. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. *J Virol* 69:263-271 (1995).
130. **Burke DS**. Review: Human trials of experimental HIV vaccines. *AIDS* 9:S171-S180 (1995).
131. Loomis LD, Deal CD, Kersey KS, **Burke DS**, Redfield RR, Birx DL. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. *J AIDS* 10:13-26 (1995).

132. Artenstein AW, VanCott TC, Mascola JR, Carr JK, Hegerich PA, Gaywee J, Sanders-Buell E, Robb ML, Dayhoff DE, Thitvichianlert S, Nitayaphan S, McNeil JG, Birx DL, Michael RA, **Burke DS**, McCutchan FE. Dual infection with Human Immunodeficiency Virus type 1 of distinct envelope subtypes in humans. *J Infect Dis* 171:805-810 (1995).
133. Salminen MO, Koch C, Sanders-Buell E, Ehrenberg PK, Michael NL, Carr JK, **Burke DS**, McCutchan FE. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. *Virology* 213:80-86 (1995).
134. Brodine SK, Mascola JR, Weiss PJ, Ito SI, Porter KR, Artenstein AW, Garland FC, McCutchan FE, **Burke DS**. Detection of diverse HIV-1 genetic subtypes in the USA. *Lancet* 346:1198-1199 (1995).
135. Michael NL, Mo T, Merzouki A, O, Shaughnessy M, Oster C, **Burke DS**, Redfield RR, Birx DL, Cassol SA. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. *J Virol* 69:1868-1877 (1995).
136. VanCott TC, Bethke FR, **Burke DS**, Redfield RR, Birx DL. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. *J Immunol* 155:4100-4110 (1995).
137. Renzullo PO, McNeil JG, Wann ZF, **Burke DS**, Brundage JF. Human immunodeficiency virus type-1 seroconversion trends among young adults serving in the United States Army, 1985 - 1993. *JAIDS* 10:177-185 (1995).
138. Brown AE, Lane JR, Wagner KF, Zhou S, Chung R, Ray KL, Blatt SP, **Burke DS**. Rates of p24 antigenemia and viral isolation in comparable white and black HIV-infected subjects. *AIDS* 9:325-328 (1995).
139. Artenstein AW, Coppola J, Brown AE, Carr JK, Sanders-Buell E, Galbarini E, Mascola JR, VanCott TC, Schonbrood P, McCutchan FE, **Burke DS**. Multiple introductions of HIV-1 subtype E into the western hemisphere. *Lancet* 346:1197-1198 (1995).
140. Salminen MO, Carr JK, **Burke DS**, McCutchan FE. Identification of breakpoints in intergenotypic recombinants of HIV type-1 by bootscanning. *AIDS Res Hum Retroviruses* 11:1423-1425 (1995).
141. **Burke DS**. Joseph-Alexander Auzias-Turrene, Louis Pasteur, and early concepts of virulence, attenuation, and vaccines. *Perspect Biol Med* 39:171-186 (1996).
142. Brown AE, Brundage JF, Tomlinson JP, **Burke DS**. The U.S. Army HIV testing program: The First Decade. *Military Med* 161:117-122 (1996).
143. Brown AE, Newby JH, Ray KL, Jackson JN, **Burke DS**. Prevention and treatment of HIV infection in minorities in the U.S. Military: A Review of Military Research. *Military Med* 161:123-127 (1996).
144. Wong MT, Dolan MJ, Kozlow E, Doe R, Melcher GP, **Burke DS**, Boswell RN, Vahey M. Patterns of virus burden and T-cell phenotype are established early and are correlated with the rate of disease progression in Human Immunodeficiency Virus type 1 - infected persons. *J Infect Dis* 173:877-887 (1996).
145. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, **Burke DS**. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. *J Infect Dis* 173:340-348 (1996).
146. McCutchan FE, Artenstein AW, Sanders-Buell E, Salminen MO, Carr JK, Mascola JR, Yu X-F, Nelson KE, Khamboonruang C, Schmitt D, Kieny MP, McNeil JG, **Burke DS**. Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa. *J Virol* 70:3331-3338 (1996).
147. Sirisopana N, Torugsa K, Mason CJ, Markowitz LE, Jugsudee A, Supamongse T, Chuenchitra C, Michael RA, **Burke DS**, Singharaj P, Johnson AE, McNeil JG, McCutchan FE, Carr JK. Correlates of HIV-1 seropositivity among young men in Thailand. *AIDS Hum Retro* 11:492-498 (1996).

148. Chiang PK, McCann PP, Land JR, Pankaskie M, **Burke DS**, Mayers DL. Anti-human immunodeficiency virus (HIV-1) activities of inhibitors of polyamine pathways. *J Biomed Sci* 3: 78-81 (1996).
149. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jogodzinski L, Wagner KF, Mayers DL, **Burke DS**, Weislow OS, St. Louis DC, June CH. Antiviral effect from CD28 costimulatory receptor mediates ex vivo C4 T cell expansion from patients with HIV-1 infection. *Science* 272: 1939-1943 (1996).
150. Carr JK, Salminen MO, Koch C, Gotte D, Artenstein AW, Hegerich PA, St. Louis D, **Burke DS**, McCutchan FE. Full length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. *J Virol* 70: 5935 - 5943 (1996).
151. Salminen MO, Johansson B, Sonnerborg A, Ayeahunie S, Gotte D, Leinikki P, **Burke DS**, McCutchan FE. Full-length sequence of an Ethiopian human immunodeficiency virus. *AIDS Res Hum Retroviruses* 12:1329-1339 (1996).
152. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, **Burke DS**. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. *AIDS Res Hum Retroviruses* 12:1319-1328 (1996).
153. Michael NL, Davis KE, Loomis-Price LD, VanCott TC, **Burke DS**, Redfield RR, Birx DL. V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1 infected patients. *AIDS* 10:121-129 (1996).
154. Kim JH, McLinden RJ, Mosca JD, **Burke DS**, Boswell RN, Birx DL, Redfield RR. Transcriptional effects of superinfection in HIV chronically infected T cells: studies in dually infected clones. *J Acquir Immune Defic Syndr Hum Retrovirol* 12:329-342 (1996).
155. Gardner LI, Harrison SH, Hendrix CW, Blatt SP, Wagner KF, Chung RC, Harris RW, Cohn DL, **Burke DS**, Mayers DL. Size and duration of zidovudine benefit in 1003 HIV-infected patients: US Army, Navy and Air Force natural history data. *J Acquir Immune Defic Syndr Hum Retrovirol* 17: 345-53 (1997).
156. Porter KR, Mascola JR, Hupudio H, Ewing D, VanCott TC, Anthony RL, Corwin AL, Widodo S, Ertano S, McCutchan FE, **Burke DS**, Hayes CG, Wignall FS, Graham RR. Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia. *J Acquir Immune Defic Syndr Hum Retroviral* 14:1-6 (1997).
157. Evans JS, Nims T, Cooley J, Bradley W, Jagodzinski L, Zhou S, Melcher GP, **Burke DS**, Vahey M. Serum levels of virus burden in early-stage HIV-1 disease in women. *J Infect Dis* 175: 795-800 (1997).
158. Kim JH, Loveland JE, Sitz KV, Ratto Kim S, McLinden RJ, Tencer K, Davis K, **Burke DS**, Boswell RN, Redfield RR, Birx DL. *Clin Exp Immunol* 108: 243-50 (1997).
159. Pope M, Frankel S, Mascola JR, Trkola A, Isdell F, Birx DL, **Burke DS**, Ho DD, Moore JP. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell - T-cell mixtures without displaying subtype -specific tropism. *J Virol* 71: 8001-8007 (1997).
160. Salminen MO, Carr JK, Robertson DL, Hegerich P, Gotte D, Koch C, Sanders-Buell E, Gao F, Sharp PM, Hahn BH, **Burke DS**, McCutchan FE. Evolution and probable transmission of inter-subtype recombinant HIV-1 in a Zambian couple. *J Virol* 71:2647-55 (1997).
161. **Burke DS**. Recombination in HIV: An important viral evolutionary strategy. *Emerg Infect Dis* 3: 253-259 (1997).
162. Gardner LI, Harrison SH, Hendrix CW, Blatt SP, Wagner KF, Chung RC, Harris RW, Cohn DL, **Burke DS**, Mayers DL. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. *Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr Hum Retrovirol* 17(4):345-53 (1998)
163. **Burke DS**, DeJong KA, Grefenstette JJ, Ramsey CL, Wu AS. Putting more genetics into genetic algorithms. *Evolutionary Computation Journal* 6:387-410 (1998).

164. Ramsey CL, DeJong KA, Grefenstette JJ, Wu AS, **Burke DS**. Genome length as an evolutionary self-adaptation. *Parallel Problem Solving from Nature* 5: 345-353 (1998).
165. Wu AS, DeJong KA, **Burke DS**, Grefenstette JJ, Ramsey CL. Visual analysis of evolutionary algorithms. *Proceedings of the 1999 congress on Evolutionary Computation* 2:1419-1425 (1999).
166. Wolfe ND, Eitel MD, Gockowski J, Muchaal PK, Nolte C, Prosser AT, Torimiro JN, Weise SF, **Burke DS**. Deforestation, hunting, and the ecology of microbial emergence. *Global Change and Human Health* 1: 1-5 (2000)
167. Hay SI, Myers MF, **Burke DS**, Vaughn DW, Endy T, Ananda N, Shanks GD, Snow RW, Rogers DJ. Etiology of interepidemic periods of mosquito-borne disease. *Proc Natl Acad Sci USA* 97: 9337-9339 (2000).
168. Carr JK, Torimiro JN, Wolfe ND, Eitel MN, Kim B, Sanders-Buell E, Jagodzinski LL, Gotte D, **Burke DS**, Birx DL, Mc Cutchan FE. The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon. *Virology* 286: 168-81(2001).
169. Esparza J, **Burke DS**. Epidemiological considerations in planning HIV preventive vaccine trials. *AIDS* 15 Suppl 5:S49-57 (2001).
170. Epstein JM, Cummings DAT, Chakravarty S, Singa RM, **Burke DS**. Toward a containment strategy of smallpox bioterror: An individual-based computational approach. *Brookings Institution Center on Social and Economic Dynamics Working Paper No. 31* (2002).
171. Nisalak A, Endy TP, Nimmannitya S, Kalayanaroj S, Thisayakorn U, Scott RM, **Burke DS**, Hoke CH, Innis BL, David W. Vaughn DW. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. *Amer J Trop Med Hyg* 68:191-202 (2003).
172. Oh S, Hodge JW, Ahler JD, **Burke DS**, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. *J Immunol* 170: 2523-30 (2003).
173. Oh S, Berzofsky JA, **Burke DS**, Waldmann TA, Perera LP. Co-administration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. *Proc Natl Acad Sci USA* 100: 3392-7 (2003).
174. de Bruyn G, Anthony J. Rossini AJ, Chiu Y-L, Holman D, Elizaga ML, Frey SE, **Burke DS**, Evan TG, Corey L, Keefer MC. Safety profile of recombinant canarypox HIV vaccines. *Vaccine* 22(5-6):704-13 (2004)
175. Cummings DAT, Irizarry RA, Huang NE, Endy TP, Nisalak A, Ungchusak K, **Burke DS**. Traveling waves in the occurrence of dengue hemorrhagic fever in Thailand. *Nature* 427. 344-347 (2004).
176. Wolfe ND, Switzer WM, Carr JK, Vinod B, Bhullar VB, Vedapuri Shanmugam V, Tamoufe U, Prosser AT, Torimiro JN, Wright, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, **Burke DS**, Heneine W. Naturally acquired simian retrovirus infections among Central African hunters. *Lancet* 363(9413):932-7 (2004).
177. Kijak GH, Sanders-Buell E, Wolfe ND, Mpoudi-Ngole E, Kim B, Brown B, Robb ML, Birx DL, **Burke DS**, Carr JK, McCutchan FE. Development and application of a high-throughput HIV type 1 genotyping assay to identify CRF02_AG in West/West Central Africa. *AIDS Res Hum Retroviruses*. 20(5):521-530 (2004)
178. Oh S, Perera LP, **Burke DS**, Waldmann TA, Berzofsky JA. IL-15/IL-15R alpha-mediated avidity maturation of memory CD8+ T cells. *Proc Natl Acad Sci U S A*. 101(42):15154-15159 (2004)
179. Waters HR, Dougherty L, Tegang S-P, Tran N, Wiysonge CS, Long K, Wolfe ND, **Burke DS**. Coverage and costs of childhood immunization in Cameroon. *Bull World Hlth Org* 82: 668-675 (2004).
180. Wolfe ND, Prosser AT, Carr JK, Tamoufe U, Mpoudi-Ngole E, Torimiro JN, LeBreton M, McCutchan FE, Birx DL, **Burke DS**. Exposure to nonhuman primates in rural Cameroon. *Emerg Infect Dis* 10: 2094-2099 (2004).
181. **Burke DS**. Lessons learned from the 1954 Field Trial of Poliomyelitis Vaccine. *Clinical Trials* 1: 3-5. (2004).

182. Nguyen JC, Murphy ME, Nutman TB, Neafie RC, Maturo S, **Burke DS**, Turiansky GW. Tropical Medicine Rounds: Cutaneous onchocerciasis in an American traveler. *Intl J Dermatol* 44:125-8 (2005).
183. Gilbert PB, Peterson ML, Follmann D, Francis DP, Gurwith M, Heyward WL, Hudgens MG, Jobes DV, Popovic V, Self SG, Sinangil F, **Burke DS**, Berman PW. Immunologic responses to rgp120 vaccine correlate with the incidence of HIV-1 infection in a phase 3 preventive HIV-1 vaccine trial. *J Infect Dis* 191: 666-77 (2005)
184. Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, Torimiro JN, Prosser AT, Lebreton M, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, **Burke DS**, Switzer WM. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. *Proc Natl Acad Sci U S A* 102: 7994-9 (2005).
185. Machuca A, Wood O, Lee S, Daniel S, Rios M, Wolfe ND, Carr JK, Eitel MN, Tamoufe U, Torimiro JN, **Burke D**, Hewlett IK. Seroprevalence of human T cell leukemia virus in HIV antibody-negative populations in rural Cameroon. *Clin Infect Dis* 40:1673-6 (2005).
186. Cummings DAT, Schwartz IB, Billings L, Shaw LB, **Burke DS**. Dynamic effects of antibody dependent enhancement on the fitness of viruses. *Proc Natl Acad Sci USA* 102:15259-64 (2005).
187. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithworn S, **Burke DS**. Evaluation of the likely effectiveness of strategies for containing an emerging influenza pandemic in Southeast Asia. *Nature* 437:209-14 (2005).
188. Schwartz IB, Shaw LB, Cummings DAT, Billings L, McCrary M, **Burke DS**. Chaotic desynchronization of multistrain diseases. *Physical Review E* 72 (066201): 1- 6 (2005)
189. Wolfe ND, Daszak P, Kilpatrick AM, **Burke DS**. Bushmeat hunting, deforestation, and prediction of zoonotic disease. *Emerging Infect Dis* 11: 1822-27 (2005). :
190. Kalish ML, Wolfe ND, Ndongmo CB, McNicholl J, Robbins KE, Aidoo M, Fonjungo PN, Alemnji G, Zeh C, Djoko CF, Mpoudi-Ngole E, **Burke DS**, Folks TM. Central African hunters exposed to simian immunodeficiency virus. *Emerg Infect Dis* 11:1928-30 (2005). :
191. Torimiro JN, Carr JK, Wolfe ND, Karacki P, Martin MP, Gao X, Tamoufe U, Thomas A, Ngole EM, Birx DL, McCutchan FE, **Burke DS**, Carrington M. HLA class I diversity among rural rainforest inhabitants in Cameroon: identification of A*2612-B*4407 haplotype. *Tissue Antigens* 67: 30-7 (2006).
192. Cummings DAT, Moss WJ, Long K, Muluh TJ, Kollo B, Nomo E, Wolfe ND, **Burke DS**. Improved measles surveillance in Cameroon reveals two major dynamic patterns of incidence. *Int J Infect Dis* 10: 148-55 (2006)
193. Kuniholm MH, Wolfe ND, Huang CY, Mpoudi-Ngole E, Tamoufe U, **Burke DS**, Gubler DJ. Seroprevalence and distribution of Flaviviridae, Togaviridae, and Bunyaviridae arboviral infections in rural Cameroonian adults. *Am J Trop Med Hyg* 74: 1078-83 (2006).
194. LeBreton M, Umlauf S, Djoko CF, Daszak P, **Burke DS**, Kwenkam PY, Wolfe ND. Rift Valley fever in goats, Cameroon. *Emerg Infect Dis* 12: 702-3 (2006)
195. Oh S, Stegman B, Pendleton CD, Ota MO, Pan CH, Griffin DE, **Burke DS**, Berzofsky JA. Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus. *Virology* 352: 390-9 (2006).
196. Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, Schechter M, Mbewe B, Vardas E, Pitisuttithum P, **Burke D**, Freed D, Mogg R, Coplan PM, Condra JH, Long RS, Anderson K, Casimiro DR, Shiver JW, Straus WL. Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. *J Acquir Immune Defic Syndr* 42: 135-9 (2006).
197. Switzer WM, Qari S, Wolfe ND, **Burke DS**, Folks TM, Heneine W. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. *J Virol* 80: 7427-38 (2006).
198. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, **Burke DS**. Strategies for mitigating an influenza pandemic. *Nature* 442: 448-52 (2006).

199. **Burke DS**, Epstein JM, Cummings DA, Parker JI, Cline KC, Singa RM, Chakravarty S. Individual-based computational modeling of smallpox epidemic control strategies. *Acad Emerg Med* 13: 1142-9 (2006).
200. Longini IM Jr, Elizabeth Halloran M, Nizam A, Yang Y, Xu S, **Burke DS**, Cummings DA, Epstein JM. Containing a large bioterrorist smallpox attack: a computer simulation approach. *Int J Infect Dis* 11: 98-108 (2007).
201. Switzer WM, Hewlett I, Aaron L, Wolfe ND, **Burke DS**, Heneine W. Serologic testing for human T-lymphotropic virus-3 and -4. *Transfusion* 46: 1647-8 (2006).
202. Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, Heppner DG, Jedlicka AE, Scott AL, Wolfe ND, Vahey M, **Burke DS**. Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. *Infect Immun* 74: 5561-73 (2006).
203. Billings L, Schwartz IB, Shaw LB, McCrary M, **Burke, DS**, Cummings DA. Instabilities in multiserotype disease models with antibody-dependent enhancement. *J Theoretical Biology* 246: 18-27 (2007).
204. Torimiro JN, Wolfe ND, Thomas A, Martin MP, Mpoudi-Ngole E, Tamoufe U, Birx DL, Carrington M, **Burke DS**, Carr JK. Frequency of CCR5 variants among rural populations with low HIV-1 prevalence in Cameroon. *AIDS* 21: 527-8 (2007).
205. Lessler J, Cummings DA, Fishman S, Vora A, **Burke DS**. Transmissibility of swine flu at Fort Dix, 1976. *J Royal Soc Interface* 4: 755-62 (2007).
206. Vora A, **Burke DS**, Cummings DA. The impact of a physical geographic barrier on the dynamics of measles. [Electronic publication ahead of print] *Epidemiol Infect.* Jul 30, 2007: 1-8 (2007).
207. LeBreton M, Yang O, Tamoufe U, Mpoudi-Ngole E, Torimiro JN, Djoko CF, Carr JK, Prosser AT, Rimoin AE, Birx DL, **Burke DS**, Wolfe ND. Exposure to Wilde Primates among HIV-infected Persons, *EMERG Infect Dis* Oct 13(10): 1579-81 (2007).
208. Halloran ME, Ferguson NM, Eubank S, Longini IM, Cummings DA, Lewis B, Xu S, Fraser C, Vullikanti A, Germann TC, Wagener D, Beckman R, Kadau K, Barrett C, Macken CA, **Burke DS**, and Cooley P. Modeling targeted layered containment of an influenza pandemic in the United States, *PNAS* 10:1073 (2008).

Books

1. **Burke DS** (Chairman). *Under The Weather: Climate, Ecosystems, and Infectious Disease*. National Academy Press, Washington DC, 2001.

Book Chapters / Mongraphs

1. **Burke DS**, Chutichedej P, Boongrapu P, Narendar Pal Singh. Studies of viral hepatitis at Pramongkutklao Hospital, pp 134-150 in *Viral Hepatitis in Thailand*, Ed. Wasi C and Thongcharoen P, Aksorn Samai, Bangkok (in Thai language, 1983).
2. **Burke DS**. The prospects for immunizing against Japanese encephalitis. In *Priorities for New Vaccine Development, Part II*. National Academy of Sciences, Washington, DC (1987).
3. Binn LN, Bancroft WH, Eckels KH, Marchwicki RH, Dubois DR, Asher LVS, LeDuc JW, Trahan CJ, **Burke DS**. Inactivated hepatitis A virus vaccine produced in human diploid MRC-5 cells. In Zuckerman AJ (ed.): *Viral Hepatitis and Liver Disease*. New York: Alan R. Liss, Inc., pp 91-93 (1988).
4. Sjorgren MH, Eckels KH, Binn LN, Dubois DR, Hoke CH, **Burke DS**, Bancroft WH. Safety and immunogenicity of an inactivated hepatitis A vaccine. In Zuckerman AJ (ed): *Viral Hepatitis and Liver Disease*. New York: Alan R. Liss, Inc., pp 94-96 (1988).
5. **Burke DS**, Leake CJ. Japanese encephalitis. Chapter 28 in *The Arboviruses: Epidemiology and Ecology*, Volume III, pages 63-92. CRC Press, Inc. Boca Raton, FL (1988).

6. **Burke DS**, McCutchan FE. Global Distribution of Human Immunodeficiency Virus-1 Clades, chapter 7 in *AIDS, Biology, diagnosis, Treatment and Prevention*, fourth edition, ed. VT DeVita, S Hellman, SA Rosenberg. Lippincott-Raven Publishers (1996).
7. **Burke DS**. Vaccine Therapy. Chapter 67 in *New Generation Vaccines*, Second Edition, second edition, ed. Levine MM, Woodrow GC, Kaper JB, and Cobon GS, Marcel Decker, Inc., New York (1997).
8. **Burke DS**. Evolvability of Emerging Viruses. Chapter 1 in *Pathology of Emerging Infections*, ed. Nelson AM and Horsburgh CR, American Society of Microbiology, Washington DC (1998).
9. **Burke DS**. HIV and AIDS in the United States Military. Chapter in *The Oxford Companion to American Military History*, ed. Chambers JW (2000).
10. **Burke DS**. AIDS and AIDS-Related Infections. Chapter 114 in *Essentials of Tropical Infectious Diseases: Principles, Pathogens, and Practice*, ed. Guerrant RL, Weller PF, and Walker DH, W.B. Saunders Company, Philadelphia (2000).
11. **Burke DS** and Monath TP. Flaviviruses. Chapter 33 (pp. 1043-1126) in *Field's Virology*, 4th Edition, Editors Knipe DM and Howley PM, Lippincott Williams & Wilkins, Philadelphia, (2001).
12. **Burke DS**. Vaccine Therapy. Chapter in *New Generation Vaccines*, Third Edition, ed. Levine MM, Woodrow GC, Kaper JB, and Cobon GS, Marcel Decker, Inc., New York (2004)
13. Epstein JM, Cummings DAT, Chakravarty S, Singa RM, **Burke DS**. Toward a containment strategy for smallpox bioterror: An individual-based computational approach. Brookings Institution Press, Washington DC (2004)

Book Reviews

1. **Burke DS**. Louis Pasteur. J Amer Med Assoc 283: 2587-2588 (2000).
2. **Burke DS**. The Politics of International Health. Bull Hist Med 74: 650-651 (2000).
3. **Burke DS**. The Vaccine Book. J Amer Med Assoc 290: 406-407 (2003).
4. **Burke DS**. Six Modern Plagues and How We Are Causing Them. Env Health Perspectives 112: A66 (2004).

Letters to the Editor

1. **Burke DS**, Rushforth NB. Inhibition of pacemaker activity in Hydra. Amer Zool 6:91 (letter, 1966).
2. **Burke DS**. Magic shotgun pellets. Lancet 1:1414 (letter, 1979).
3. Henderson A, Leake CJ, **Burke DS**. Japanese encephalitis in Nepal. Lancet 2:1359-1360 (letter, 1983).
4. **Burke DS**, Ussery MA, Elwell MR, Nisalak A, Leake C, Laorakpongse T. Isolation of Japanese encephalitis strains from sentinel pigs in northern Thailand, 1982. Trans Roy Soc Trop Med Hyg 79:420-421 (letter, 1985).
5. **Burke DS**, Nisalak A, Nimmannitya S. Disappearance of chikungunya virus from Bangkok. Trans Roy Soc Trop Med Hyg 79:419-420 (letter, 1985).
6. Wattanavijarn W, Tesprateep T, **Burke DS**. Absence of porcine parvovirus transmission to man. Trans Roy Soc Trop Med Hyg 79:561 (letter, 1985).
7. **Burke DS**, Redfield RR. False positive Western blot tests for antibodies to HTLV-III. J Am Med Assoc 256:347 (letter, 1986).
8. Kelley PW, Redfield RR, Ward DL, **Burke DS**, Miller RN. Prevalence and incidence of HTLV-III infection in a prison. J Am Med Assoc 256:2198-2199 (letter, 1986).
9. **Burke DS**, Redfield RR. Classification of infections with Human Immunodeficiency Virus. Ann Int Med 105:968 (letter, 1986).
10. Lennox JF, Redfield RR, **Burke DS**. HIV antibody screening in a general hospital population. J Am Med Assoc 257:2914 (letter, 1987).

11. **Burke DS**, Redfield RR. Transmission of Human Immunodeficiency Virus (HIV). *N Engl Med* 318:1202-1203 (letter, 1988).
12. **Burke DS**. Review of laboratory proficiency. *Infect Control Hosp Epidemiol* 9:365 (letter, 1988).
13. **Burke DS**, Brundage JF, Redfield RR, Damato JJ. Screening for Human Immunodeficiency Virus infections. *N Engl J Med* 320:461-463 (letter, 1989).
14. **Burke DS**, Redfield RR, Bjornson DC, Fowler AK, Oster CN. Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy. *N Engl J Med* 321:1682 (letter, 1989).
15. Malone JL, Oldfield EC; Wagner KF, Simms TE, Daly R, O'Brian J, **Burke DS**. Abnormalities of morning serum cortisol levels and circadian rhythms of CD4+ lymphocyte counts in human immunodeficiency virus type 1-infected adult patients (letter). *J Infect Dis* 165:185-186 (letter, 1992).
16. Roy MJ, Damato JJ, **Burke DS**. Absence of seroreversion of HIV-1 antibody in seroreactive individuals. *J Am Med Assoc* 270:2179 (letter, 1993).
17. **Burke DS**, Brown AE. Screening surgeons for HIV infection. *Ann Intern Med* 123:812-813 (letter, 1995).
18. Brown AE, **Burke DS**. Cost of HIV testing in the U.S. Army. *N Eng J Med* 332:963 (letter, 1995).
19. **Burke DS**. Another look at Microbe Hunters. *Amer Soc Microbiol News* 8: 403 (letter, 1997).
20. **Burke DS**, Kliks S. Antibody dependent enhancement in dengue virus infections. *J Infect Dis* 193: 601-603 (2006).

Editorials / Other

1. **Burke DS**. A strategy to prevent the spread of AIDS. *The Saturday Evening Post*, May/June, pp. 22, 91 (1988).
2. **Burke DS**. The threat posed by dengue virus infection. *Infect Med* 5:499-510 (1988).
3. **Burke DS**. Introduction to the 1991 ASTMH Presidential Address. *Am J Trop Med Hyg* 46:239-240 (1992).
4. **Burke DS**. Amsterdam AIDS Conference reveals slow progress (news). *Critical Care Nurse* 12:98-99 (1992).
5. **Burke DS**. HIV infection and AIDS: Editorial overview. *Curr Opp Infect Dis* 6:179-180 (1993).
6. Mascola JR, McNeil, JG, **Burke DS**. AIDS vaccines. Are we ready for human efficacy trials? *J Am Med Assoc* 272:488-489 (1994).
7. **Burke DS**. 1996 American Society of Tropical Medicine and Hygiene President's Address. Sing for the Gov'nor: A call to advocacy for tropical medicine and hygiene. *Am J Trop Med Hyg* 56:1-6 (1997).
8. **Burke DS**. Six Months to Act (Op-Ed on SARS). *Wall Street Journal*, 25 April 2003 (2003).
9. **Burke DS**. Ignoring Deadly Viruses (Op-Ed on avian influenza). *Asian Wall Street Journal*, 26 January 2004 (2004).
10. **Burke DS**. Avian Influenza Is a Threat To Our Collective Security (Op-Ed). *Wall Street Journal*, 3 November 2005 (2005)



COUNTY OF ALLEGHENY

OFFICE OF THE COUNTY COUNCIL
119 COURTHOUSE • 436 GRANT STREET
PITTSBURGH, PA 15219
PHONE (412) 350-6490 • FAX (412) 350-6499
COUNCIL@COUNTY.ALLEGHENY.PA.US
WWW.COUNTY.ALLEGHENY.PA.US/COUNCIL

August 26, 2008

Donald Scott Burke, M.D.
130 DeSoto Street, Room A624
Pittsburgh, PA 15261

Dear Dr. Burke:

This is to inform you that an Appointment Review Committee Meeting has been scheduled for **4:00 PM, Thursday, September 11, 2008** in Conference Room One, 119 County Courthouse.

Your presence has been requested to discuss your nomination for appointment to the Allegheny County Board of Health.

If you have any questions regarding this please contact me at 412-350-6495.

Sincerely,

A handwritten signature in cursive script that reads "John Mascio".

John Mascio
Chief Clerk
Allegheny County Council

JM/fb